Business Context and Reporting Period
Company: Forte Biosciences, Inc. (formerly Tocagen Inc.)
Filing Date: September 4, 2020
Reporting Period: Current Report (8-K) covering events on September 4, 2020, and updates regarding the June 15, 2020 business combination.
Business Overview: Forte is a clinical-stage biopharmaceutical company focused on developing FB-401, a live biotherapeutic for the treatment of inflammatory skin diseases, specifically atopic dermatitis (AD). The company completed a reverse stock split (15-for-1) and a name change in connection with its merger with Forte Subsidiary, Inc.
Key Financial Metrics
Revenue, Profit, and Cash Flow: The filing text does not provide specific revenue, profit, or cash flow figures for the current period. Forte is a clinical-stage company with no commercial sales organization established to date.
Debt and Liquidity: The filing does not disclose specific debt balances or liquidity positions. However, the company is entering into a new financing arrangement to fund operations.
Capital Raising: Forte entered into an At Market Issuance Sales Agreement to offer and sell common stock with an aggregate offering price of up to $30,000,000.
Intellectual Property Obligations: Under a license with the U.S. Department of Health and Human Services (DHHS), Forte is obligated to pay a minimum annual royalty of $100,000 (effective Jan 1, 2021) and potential milestone payments totaling up to $40.5 million. Royalties on net sales range from 5% to 10%.
Material Changes
- Equity Distribution Agreement: Forte terminated its previous Equity Distribution Agreement with Citigroup Global Markets Inc. and entered into a new At Market Issuance Sales Agreement with Ladenburg Thalmann & Co. Inc. on September 4, 2020.
- Corporate Structure: Completed a business combination with Forte Subsidiary, Inc. on June 15, 2020, resulting in a name change from "Tocagen Inc." to "Forte Biosciences, Inc." and a 15-for-1 reverse stock split.
- Intellectual Property: Amended its exclusive license agreement with DHHS in May 2020, reducing total milestone payments from $105.5 million to $40.5 million and lowering royalty rates from 10-15% to 5-10%.
Guidance, Outlook, and Risks
Outlook and Strategy:
- Clinical Development: Forte plans to initiate a Phase 2 clinical trial for FB-401 in the third quarter of 2020. Full results from the completed Phase 1/2a study are expected to be published within one to two months of the filing.
- Use of Proceeds: Net proceeds from the new sales agreement will fund ongoing clinical development of FB-401, existing and potential new clinical programs, and general corporate purposes.
- Commercialization: No commercial organization exists yet. Future plans include building a sales team and/or partnering with third parties upon FDA approval.
- Forward-Looking Statements: Actual results may differ materially due to risks regarding cash sufficiency, clinical trial timing, regulatory approvals, and the impact of COVID-19.
- Manufacturing: Forte relies on a single-source third-party contract manufacturer for FB-401; supply disruption could limit development.
- Regulatory: Significant risks exist regarding FDA approval, compliance with healthcare laws (Anti-Kickback, False Claims Act), and potential changes in healthcare reform legislation affecting pricing and reimbursement.
- Intellectual Property: Success depends on maintaining patent protection and defending against third-party challenges.
Investor Verification Checklist
- Verify the terms of the new At Market Issuance Sales Agreement with Ladenburg Thalmann & Co. Inc., specifically the 3.0% commission and termination rights.
- Confirm the timeline and enrollment status for the planned Phase 2 clinical trial for FB-401.
- Review the full text of the amended DHHS license agreement to understand specific milestone triggers and royalty obligations.
- Assess the company's current cash runway and the necessity of additional financing beyond the $30 million ATM facility.
- Monitor the publication of full Phase 1/2a study results to validate the safety and efficacy data presented in the filing.